This early-phase trial tests a personalized vaccine (ALZN002) made from a patient's own immune cells, designed to train the body to attack amyloid plaques in the brain. Thirty people with mild-to-moderate Alzheimer's will receive either the vaccine or a placebo. The main goal is …
Phase: PHASE1, PHASE2 • Sponsor: Alzamend Neuro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:08 UTC